Search Results  for '4153.TWO'

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

DIVA Laboratories Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

30 Apr 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - DIVA Laboratories Ltd (4153-OT)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

20 May 2016 Thomson Reuters Stock Report 11 $25.00

Thomson Reuters Stock Report - DIVA Laboratories Ltd (4153-OT)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

05 May 2016 Thomson Reuters Stock Report 11 $25.00

Wright Investors Service Comprehensive Report for Diva Laboratories Ltd

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

30 Apr 2016 Wright Reports 54 $75.00

Diva Laboratories Ltd: Downgraded to Above Average

07 Apr 2016 Sadif Analytics Prime 3 $10.00

Diva Laboratories Ltd: Upgraded to Good

08 Feb 2016 Sadif Analytics Prime 3 $10.00

鈺緯 (4153):靜待客戶釋單,上半年營運動能仍疲弱

元富預估鈺緯2016年營收16億元(YOY +19%),其中母公司營收12億元(YOY +16%),成長來自醫療顯示器訂單,富動營收為4.0億元(YOY +30%),因為打入歐洲經銷商客戶;由於醫療顯示器新客戶屬於直接銷售,毛利率高達50%,且鈺緯將...

02 Feb 2016 MasterLink Securities Corporation 4 $23.00

Diva Laboratories Ltd: Upgraded to Above Average

03 Jun 2015 Sadif Analytics Prime 3 $10.00

鈺緯 (4153):子公司富動2015年營運大幅低於預期

展望2015年,元富預估鈺緯營收15億元,YOY +65%,成長動能來自(1) 3Q14開始供應Roche旗下的醫療系統廠Ventana,(2)1Q15併購的子公司富動,(3)新客戶美國醫材通路商;鈺緯並持續進行代理轉直接銷售,且切入高毛利的顯示器應...

21 May 2015 MasterLink Securities Corporation 5 $35.00

Diva Laboratories Ltd: Downgraded to Average

22 Jan 2015 Sadif Analytics Prime 3 $10.00